Zydus' Virafin Gets Emergency Use Approval For Treating Moderate Covid Cases

This government's approval for use of the antiviral drug comes at a time when India's daily COVID tally is crossing the 3-lakh mark.

The Drugs Controller General of India (DGCI) has approved emergency use for Zydus Cadila's Pegylated Interferon alpha-2b, "Virafin" for treating moderate COVID-19 infection in adults. A release by Cadila Health said, "The drug has also shown efficacy against other viral infections." Speaking on the development, Dr Sharvil Patel, Managing Director, Cadila Healthcare Limited said: "The fact that we are able to offer a therapy which significantly reduces viral load when given early on can help in better disease management. It comes at a much-needed time for patients and we will continue to provide them access to critical therapies in this battle against COVID-19." This government's approval for use of the antiviral drug comes at a time when India's daily COVID tally is crossing the 3-lakh mark.